Business Context and Reporting Period
This Form 8-K, filed on April 13, 2017, by Abbott Laboratories, reports the entry into a material definitive agreement regarding the acquisition of Alere Inc. The filing details an amendment to the previously announced Agreement and Plan of Merger dated February 2, 2016.
Key Financial Metrics and Transaction Terms
- Merger Consideration: Reduced from $56.00 to $51.00 in cash per share of Alere common stock.
- Termination Fee: Reduced from $177 million to $161 million payable by Alere under specified circumstances.
- Transaction Timeline: The termination date for the agreement has been extended to September 30, 2017.
- Employee Benefits: Abbott's commitment to maintain specified compensation and benefits for continuing Alere employees is now limited to the first anniversary of the Effective Time, rather than through December 31, 2017.
Material Changes Versus Prior Period
The primary material change is the reduction in the purchase price per share by $5.00. Additionally, the termination fee obligation for Alere has been lowered by $16 million. The filing also notes a settlement of pending litigation in Delaware Chancery Court, resulting in the dismissal of claims with prejudice, except for specific antitrust claims which are dismissed without prejudice.
Guidance, Outlook, Risks, and Contingencies
Closing Conditions: Completion of the merger remains subject to several conditions, including shareholder approval, absence of legal injunctions, expiration of the Hart-Scott-Rodino waiting period, receipt of antitrust approvals, and the absence of a Material Adverse Effect (MAE).
MAE Definition: The amendment clarifies that matters disclosed in Alere's public filings between January 1, 2014, and April 13, 2017, or known to Abbott prior to April 13, 2017, cannot be considered in determining an MAE.
Risks: Abbott cautions that there is no guarantee the acquisition will be completed or that expected benefits will be realized. Actual financial impacts may differ from anticipated results due to economic, competitive, governmental, and technological factors.
Important Facts for Investor Verification
- Verify the final shareholder vote outcome required to approve the amended merger agreement.
- Monitor the status of antitrust approvals and the expiration of the Hart-Scott-Rodino waiting period.
- Review the specific terms of the Settlement Agreement regarding the release of claims and the status of non-released antitrust claims.
- Assess the impact of the reduced purchase price on Abbott's projected accretive impact and financial statements.